Industries

• Reset all ×
• Life Sciences ×
• 2021 ×

Showing 231–240 of 279 results

Sort by popularity Sort by average rating Sort by latest Sort by price: low to high Sort by price: high to low

• 

  Transcatheter Aortic Valve Replacement (TAVR) Product Market in China 2021

  The transcatheter aortic valve replacement (TAVR) product market in China in terms of revenue is set to grow by US$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 44.2% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the transcatheter aortic valve replacement (TAVR) product market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Prostate Cancer Drug Market in China 2021

  The prostate cancer drug market in China in terms of revenue is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 27.7% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the prostate cancer drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Microsphere Agents Market in China 2021

  The microsphere agents market in China in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 17.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the microsphere agents market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Global Prostate Cancer Drug Market 2021

  The global prostate cancer drug market in terms of revenue is set to grow by US$ 11 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.5% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the prostate cancer drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Global Biologics CDMO (Contract Development and Manufacturing Organization) Market 2021

  The global biologics CDMO (contract development and manufacturing organization) market in terms of revenue is set to grow by US$ 22 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 20.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the biologics CDMO (contract development and manufacturing organization) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Global Heparin API Market 2021

  The global heparin API market in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the heparin API market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Enoxaparin Finished Dose Market in China 2021

  The enoxaparin finished dose market in China in terms of revenue is set to grow by US$ 968 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 23.6% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the enoxaparin finished dose market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Global Enoxaparin Finished Dose Market 2021

  The global enoxaparin finished dose market in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 5.9% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the enoxaparin finished dose market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Global Heparin Finished Dose Market 2021

  The global heparin finished dose market in terms of revenue is set to grow by US$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the heparin finished dose market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450
• 

  Artificial Tears Market in China 2021

  The artificial tears market in China in terms of revenue is set to grow by US$ 514 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 13.2% during the forecast period, according to data and analytics company StrategyHelix. The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the artificial tears market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

  USD 450